{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.28","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"11.5","value":"3.3"},{"groupId":"OG001","lowerLimit":"3.3","upperLimit":"18.0","value":"8.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"description":"Positive HPV DNA status is defined as 5 or more HPV DNA fragments per mL of blood plasma, assessed by tumor-tissue modified viral (TTMV) testing.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cisplatin: 40 mg/m2 IV (intravenously) weekly for 6 weeks\n\nIMRT 6 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 6 weeks, 5 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"OG000","title":"IMRT 6 Weeks + Cisplatin (Arm 1)"},{"description":"IMRT 5 weeks: Intensity-modulated radiation therapy (IMRT), 30 fractions over 5 weeks, 6 fractions per week, 2 Gray per fraction to total dose of 60 Gy","id":"OG001","title":"IMRT 5 Weeks (Arm 2)"}],"paramType":"NUMBER","populationDescription":"Eligible participants with post-treatment HPV DNA value","reportingStatus":"POSTED","timeFrame":"Between 2 weeks to 1 month after treatment completion (approximately 6 weeks).","title":"Percentage of Participants Positive for Human Papillomavirus (HPV) Deoxyribonucleic Acid (DNA) After Treatment (Detection Rate)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}